GO:0071225 cellular response to muramyl dipeptide: NOD2 Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071225 describes how a single cell changes its state or activity in response to muramyl dipeptide (MDP), a peptidoglycan-derived bacterial motif.
• The canonical sensor is NOD2, which detects MDP and triggers RIPK2-dependent signaling, NF-kB activation and inflammatory gene expression.
• MDP responses are cell-type specific: microglia mount RIPK2-dependent inflammation, while gamma-delta T cells show a distinct response profile.
• Beyond NOD2, intracellular peptidoglycan detection can be mediated by PGLYRP1, which promotes intestinal mucosal protection.
• MDP is a powerful vaccine adjuvant that boosts humoral, cellular and mucosal immunity, and synthetic MDP-presenting polymersomes can amplify antitumor immunity.
• CRISPR knockout, knock-in, point-mutation and overexpression models are essential to dissect which genes causally drive MDP responses.
Description
Muramyl dipeptide (MDP) is the minimal bioactive fragment of bacterial peptidoglycan and a classic pathogen-associated molecular pattern. GO:0071225, cellular response to muramyl dipeptide, captures every process by which a cell changes its state or activity after encountering MDP, including movement, secretion, enzyme production and gene expression. Because MDP is shed by virtually all bacteria, this response sits at the interface of innate immunity, inflammation and host-microbe interaction. Understanding it is therefore central to infection biology, autoinflammatory disease and vaccine design. The response is best known through NOD2, the cytosolic receptor that binds MDP and recruits the kinase RIPK2 to activate NF-kB and MAPK pathways. However, recent work shows the response is not monolithic: microglial cells require RIPK2 for MDP-driven inflammation but not for lipopolysaccharide responses, and gamma-delta T cells respond to MDP in a distinct manner. Additional intracellular peptidoglycan sensors such as PGLYRP1 broaden the detection repertoire and link MDP sensing to intestinal mucosal protection. For researchers, GO:0071225 provides a precise annotation target for transcriptomic, proteomic and functional screens. It also has translational value: MDP compounds are used as vaccine adjuvants, and MDP-presenting nanoparticles are being engineered to boost systemic antitumor immunity. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanism, key genes, disease links and experimental models for studying cellular response to muramyl dipeptide.
cellular response to muramyl dipeptide At A Glance
| GO ID | GO:0071225 |
|---|---|
| GO term | cellular response to muramyl dipeptide |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that results in a change in state or activity of a cell as a result of a muramyl dipeptide stimulus; MDP is derived from peptidoglycan. |
| Major function | Detection of bacterial peptidoglycan fragments and initiation of inflammatory, antimicrobial and immune-regulatory programs. |
| Key sensor | NOD2, with contributions from PGLYRP1 and other intracellular peptidoglycan detection routes. |
| Key signaling node | RIPK2, required for microglial inflammatory responses to MDP. |
| Cell types studied | Microglia, gamma-delta T cells, intestinal epithelial cells, macrophages and antigen-presenting cells. |
| Therapeutic relevance | Vaccine adjuvants and antitumor immunotherapies based on MDP or MDP-presenting platforms. |
What Is GO:0071225?
In simple terms, GO:0071225 is the collection of all cellular changes triggered when a cell detects muramyl dipeptide. Formally, it is any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muramyl dipeptide stimulus. Muramyl dipeptide is derived from peptidoglycan, the structural polymer of bacterial cell walls, making this term a core node in antibacterial innate immune sensing.
Why Is cellular response to muramyl dipeptide Important in Cell Biology?
Cellular response to muramyl dipeptide is important because it is one of the most direct ways a host cell detects bacterial peptidoglycan and converts that detection into inflammation, antimicrobial defense and adaptive immune instruction. Dysregulation of this response is linked to inflammatory pathology, while intentional activation is exploited in vaccine adjuvants and cancer immunotherapy. Because the pathway converges on druggable kinases such as RIPK2 and on transcription factors such as NF-kB, it is a high-value target for mechanistic studies and therapeutic intervention.
• Defines the minimal peptidoglycan motif that activates cytosolic innate immune sensing.
• Provides a mechanistic entry point to NOD2-RIPK2 signaling and NF-kB-dependent inflammation.
• Explains cell-type-specific inflammatory programs, as shown in microglia versus gamma-delta T cells.
• Links intracellular peptidoglycan detection by PGLYRP1 to intestinal mucosal protection.
• Supports vaccine development, since MDP compounds enhance humoral, cellular and mucosal immunity.
• Underpins next-generation antitumor platforms such as MDP-presenting polymersomes.
• Connects to mycobacterial immunity and Freund's adjuvant biology through NOD2.
• Provides conserved immune readouts in non-mammalian models such as grass carp MKK4/MKK7.
• Offers a testable axis for adjuvant analog design, exemplified by GMTP-N-DPG.
• Creates opportunities for CRISPR-based causal gene discovery in innate immune cells.
What Happens During cellular response to muramyl dipeptide?
Recognition of muramyl dipeptide by cytosolic sensors
In simple terms: The cell first has to notice the bacterial fragment inside it.
MDP is released from peptidoglycan and gains access to the cytosol, where it is recognized by pattern-recognition receptors. NOD2 is the canonical sensor, and its engagement by MDP is the initiating event for the cellular response. Intracellular peptidoglycan detection can also be mediated by PGLYRP1, which promotes intestinal mucosal protection and broadens the sensing repertoire beyond a single receptor. This recognition step determines whether the cell commits to an inflammatory program.
RIPK2-dependent signal transduction
In simple terms: After detection, a relay kinase passes the alarm signal onward.
Following MDP recognition, the kinase RIPK2 is recruited and is required for the microglial inflammatory response to MDP, while being dispensable for lipopolysaccharide responses. This selectivity demonstrates that MDP engages a dedicated signaling module rather than a generic inflammation cascade. Downstream of RIPK2, MAPK and NF-kB pathways are activated, driving transcription of inflammatory mediators. In non-mammalian systems, MDP challenge also engages MAPK kinase modules such as MKK4 and MKK7 in intestinal immune tissue.
Transcriptional and secretory output
In simple terms: The cell switches on genes and releases immune messengers.
Activation of NF-kB and MAPK transcription factors changes gene expression, leading to production of cytokines, chemokines and antimicrobial effectors, which matches the GO definition's emphasis on secretion and gene expression. These secreted factors recruit and instruct neighboring immune cells, converting a single-cell detection event into tissue-level inflammation. The magnitude and composition of this output differ by cell type, as illustrated by the distinct gamma-delta T cell response to the NOD2 agonist MDP.
Amplification and immune instruction
In simple terms: The response can be amplified and can teach the adaptive immune system.
MDP-driven signals can act as an adjuvant, enhancing humoral, cellular-mediated and mucosal immune responses when co-administered with inactivated vaccines. Synthetic platforms that present MDP as artificial nanobacteria can boost systemic antitumor immunity, showing that the response can be deliberately amplified for therapy. Analog design further demonstrates that the strength and quality of the response can be tuned, as with GMTP-N-DPG, which preferentially induces cellular immunity to soluble antigens.
Resolution and mucosal protection
In simple terms: The response must also be contained so it protects rather than damages tissue.
Intracellular peptidoglycan detection through PGLYRP1 promotes intestinal mucosal protection, indicating that MDP responses include homeostatic and barrier-protective arms in addition to pro-inflammatory arms. The balance between activation and restraint is central to disease outcome, and NOD2 biology in mycobacterial infection and Freund's adjuvant responses illustrates how the same axis can be protective or pathogenic depending on context. Understanding resolution mechanisms is therefore as important as understanding activation.
Key Genes Involved in GO:0071225 cellular response to muramyl dipeptide
The following genes and proteins have been experimentally implicated in cellular response to muramyl dipeptide or in closely related peptidoglycan-sensing biology in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NOD2 | Canonical cytosolic receptor for muramyl dipeptide | Central sensor for MDP response studies and adjuvant biology |
| RIPK2 | Required kinase for microglial inflammatory response to MDP | Key node for dissecting MDP-specific versus LPS-specific signaling |
| PGLYRP1 | Mediates intracellular peptidoglycan detection and mucosal protection | Alternative sensing route in intestinal epithelium |
| MAPK pathway components | Transduce MDP signals to transcription | Readout for pathway activation after MDP challenge |
| MKK4 | Involved in intestinal immune response to MDP challenge in fish | Comparative immunology model for MDP signaling |
| MKK7 | Involved in intestinal immune response to MDP challenge in fish | Comparative immunology model for MDP signaling |
| NF-kB pathway components | Drive inflammatory gene expression downstream of MDP sensing | Transcriptional readout of MDP response |
| Inflammatory cytokines | Secreted effectors of the MDP response | Functional output measured in cell and animal models |
| Gamma-delta T cell receptors | Mediate distinct gamma-delta T cell response to MDP | Cell-type-specific response studies |
| Antigen-presenting cell machinery | Links MDP sensing to adaptive immunity | Adjuvant and vaccine studies |
| Mucosal immune effectors | Contribute to barrier protection after peptidoglycan detection | Intestinal protection models |
| Mycobacterial antigen machinery | Interacts with NOD2-dependent adjuvant effects | Mycobacterial immunity and adjuvant research |
| Nanoparticle/polymersome delivery components | Present MDP as artificial nanobacteria | Antitumor immunotherapy engineering |
| Adjuvant analog scaffolds | GMTP-N-DPG preferentially induces cellular immunity | Adjuvant design and structure-activity studies |
| PEDV vaccine antigen context | MDP compound adjuvant enhances responses to inactivated vaccine | Veterinary and mucosal vaccine development |
| Intestinal epithelial sensors | Detect peptidoglycan and maintain barrier function | Mucosal immunology research |
How Is cellular response to muramyl dipeptide Regulated?
Cellular response to muramyl dipeptide is regulated at multiple levels. Receptor-proximal control is exerted through NOD2 engagement and RIPK2 recruitment, and RIPK2 is specifically required for the microglial inflammatory response to MDP but not to lipopolysaccharide, indicating pathway-selective regulation. Cell-type context further shapes the response, as gamma-delta T cells display a distinct response to the NOD2 agonist MDP compared with other cell types. Tissue-level regulation involves intracellular peptidoglycan detection by PGLYRP1, which promotes intestinal mucosal protection and therefore restrains or redirects the response toward homeostasis. Pharmacological and adjuvant-level regulation is illustrated by MDP-presenting polymersomes that amplify antitumor immunity and by the analog GMTP-N-DPG that preferentially induces cellular immunity. Together, these layers determine whether MDP sensing yields protective, adjuvant-like or pathogenic inflammation.
cellular response to muramyl dipeptide and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RIPK2 | Microglial inflammatory response to bacterial MDP | RIPK2 knockout microglial cell lines and primary microglia |
| NOD2 | Mycobacterial immunity and adjuvant responses | NOD2 knockout macrophages and mycobacterial infection models |
| PGLYRP1 | Intestinal mucosal protection | PGLYRP1 knockout intestinal epithelial cells and colitis models |
| MKK4/MKK7 | Intestinal immune response to MDP challenge | Fish intestinal immune challenge models |
| Adjuvant analog targets | Vaccine adjuvant and cellular immunity | Mouse immunization and antigen-specific T cell assays |
Inflammatory and autoinflammatory signaling
Because MDP sensing converges on NF-kB and MAPK activation through RIPK2, excessive or poorly restrained signaling can drive inflammatory pathology. The requirement for RIPK2 in microglial MDP responses positions this axis as a candidate target for neuroinflammatory conditions in which bacterial peptidoglycan fragments are detected in the central nervous system. Context-dependent effects are also evident in mycobacterial infection and Freund's adjuvant biology, where NOD2 engagement shapes both protective immunity and inflammation.
Cancer immunotherapy
MDP-driven immune activation can be harnessed therapeutically. Muramyl dipeptide-presenting polymersomes acting as artificial nanobacteria boost systemic antitumor immunity, demonstrating that deliberate activation of the MDP response can enhance tumor control. This approach exploits the same sensing machinery that mediates innate detection of peptidoglycan, converting a bacterial motif into an immunotherapeutic agent.
Vaccine adjuvant and mucosal immunity
MDP compounds function as adjuvants that enhance humoral, cellular-mediated and mucosal immune responses to inactivated vaccines, as shown with a PEDV inactivated vaccine in mice. Analog design can bias the response toward cellular immunity, as demonstrated by GMTP-N-DPG, which preferentially induces cellular immunity to soluble antigens. These findings link GO:0071225 directly to vaccine development and mucosal protection strategies.
Intestinal mucosal protection
Intracellular peptidoglycan detection mediated by PGLYRP1 promotes intestinal mucosal protection, indicating that MDP-related sensing can be beneficial for barrier function rather than purely inflammatory. This protective arm is relevant to conditions in which mucosal integrity is compromised, and it highlights the need to distinguish protective from pathogenic MDP responses in disease models.
From cellular response to muramyl dipeptide-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is RIPK2 required for MDP-induced inflammation? | RIPK2 knockout microglial cells compared with wild-type |
| Does a candidate gene mediate MDP sensing? | CRISPR knockout in macrophage or epithelial cell lines followed by MDP stimulation |
| Does a disease-associated variant alter MDP response? | Point-mutation knock-in of the variant followed by MDP challenge |
| Can a tagged sensor be tracked after MDP stimulation? | Tagged knock-in of NOD2 or PGLYRP1 for imaging and proteomics |
| Does overexpression amplify the MDP response? | Overexpression of NOD2, RIPK2 or pathway components in reporter cells |
| Can MDP-based platforms boost antitumor immunity? | MDP-presenting polymersome treatment in tumor models |
How to Study the cellular response to muramyl dipeptide Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA sequencing | Global gene expression changes after MDP stimulation | Defining the transcriptional signature of GO:0071225 |
| Phosphoproteomics | Kinase-dependent phosphorylation events | Mapping RIPK2-dependent signaling nodes |
| Cytokine ELISA | Secretion of inflammatory mediators | Functional readout of MDP response |
| Antibody titer assays | Humoral immune response to adjuvanted vaccines | Vaccine adjuvant evaluation |
| T cell proliferation assays | Cellular immunity induction | Adjuvant analog comparison |
| Tumor growth monitoring | Antitumor immunity after MDP platform treatment | Cancer immunotherapy studies |
| Fluorescence imaging | Localization of sensors and signaling proteins | Intracellular peptidoglycan detection studies |
| Comparative immune challenge | Intestinal immune gene induction in non-mammalian models | Evolutionary conservation studies |
Transcriptomic profiling of MDP-stimulated cells
RNA sequencing after MDP stimulation identifies the gene expression changes that define GO:0071225, including inflammatory cytokines and NF-kB target genes. Comparing wild-type and RIPK2 knockout microglia reveals which transcriptional programs are MDP-specific versus shared with other stimuli such as lipopolysaccharide. This approach is also useful in comparative systems, where MDP challenge induces intestinal immune gene programs in fish.
Proteomic and phosphoproteomic analysis
Because the MDP response depends on kinase recruitment and phosphorylation events, phosphoproteomics can map signaling nodes downstream of NOD2 and RIPK2. Proteomic profiling of intracellular peptidoglycan detection complexes can identify interaction partners of sensors such as PGLYRP1. These methods complement transcriptomics by capturing post-translational regulation that gene expression data miss.
Functional immune assays
Cytokine secretion, antigen-specific antibody titers and T cell proliferation assays quantify the functional output of MDP responses in adjuvant and vaccine settings. Mucosal immune readouts are particularly informative because MDP compounds enhance mucosal as well as systemic immunity. Antitumor immunity can be assessed in tumor models treated with MDP-presenting platforms.
Imaging and sensor localization
Fluorescence imaging of tagged sensors and signaling proteins reveals where and when the MDP response is initiated within the cell. Tracking intracellular peptidoglycan detection by PGLYRP1 provides spatial information that complements biochemical assays. Imaging is also valuable for confirming that synthetic MDP-presenting particles engage the same sensing pathways as soluble MDP.
How CRISPR Can Be Used to Study GO:0071225 cellular response to muramyl dipeptide
Knockout
CRISPR knockout of NOD2, RIPK2 or PGLYRP1 in macrophage, microglial or epithelial cell lines provides causal evidence for their role in cellular response to muramyl dipeptide. For example, RIPK2 knockout demonstrates that the microglial inflammatory response to MDP is RIPK2-dependent while the lipopolysaccharide response is not. Knockout models are the fastest way to test whether a candidate gene is required for MDP-induced transcriptional and secretory outputs.
Point Mutation
Point-mutation knock-in allows researchers to test whether specific residues or disease-associated variants alter MDP sensing and downstream signaling. This is particularly relevant for NOD2, where variant-specific effects on peptidoglycan recognition and adjuvant responses have been studied. Point mutants can separate receptor-binding functions from signaling functions within the same protein.
Knock-in
Tagged knock-in of sensors such as NOD2 or PGLYRP1 enables imaging, immunoprecipitation and proteomic analysis of the MDP detection complex in its native genomic context. Knock-in reporter lines can also be used to monitor pathway activation in real time after MDP stimulation. These models preserve endogenous expression levels, avoiding artifacts from strong overexpression.
Overexpression
Overexpression of NOD2, RIPK2 or downstream pathway components can amplify the MDP response and make weak signaling events easier to detect. Overexpression is also useful for testing whether a gene is sufficient to enhance MDP-induced inflammatory or adjuvant-like outputs. Combining overexpression with knockout backgrounds helps distinguish sufficiency from necessity.
How EDITGENE Supports cellular response to muramyl dipeptide Research
Researchers studying cellular response to muramyl dipeptide-related genes often need to determine whether a candidate gene is causally involved in MDP sensing, signaling or immune output, rather than merely correlated with it. This requires precise genome engineering in relevant cell types, paired with functional assays such as cytokine secretion, transcriptomics and imaging. EDITGENE provides the full toolkit needed to build and validate such models.
Contact EDITGENE today to design your custom CRISPR model for cellular response to muramyl dipeptide research.
Frequently Asked Questions About cellular response to muramyl dipeptide
What is GO:0071225 cellular response to muramyl dipeptide?
GO:0071225 is a Gene Ontology biological process term describing any change in a cell's state or activity, such as movement, secretion, enzyme production or gene expression, caused by muramyl dipeptide, a peptidoglycan-derived bacterial motif.
What genes are involved in cellular response to muramyl dipeptide?
Key genes include NOD2, the canonical MDP sensor, RIPK2, which is required for the microglial inflammatory response to MDP, and PGLYRP1, which mediates intracellular peptidoglycan detection and mucosal protection.
Why is RIPK2 important for muramyl dipeptide responses?
RIPK2 is crucial for the microglial inflammatory response to MDP but not to lipopolysaccharide, showing that MDP engages a dedicated RIPK2-dependent signaling module.
How does muramyl dipeptide activate immune cells?
MDP is detected by cytosolic sensors such as NOD2, which recruit RIPK2 and activate NF-kB and MAPK pathways, leading to inflammatory gene expression and cytokine secretion.
Is muramyl dipeptide used as a vaccine adjuvant?
Yes, MDP compounds enhance humoral, cellular-mediated and mucosal immune responses to inactivated vaccines, as demonstrated with a PEDV inactivated vaccine in mice.
Can muramyl dipeptide boost antitumor immunity?
MDP-presenting polymersomes acting as artificial nanobacteria have been shown to boost systemic antitumor immunity.
What is the role of PGLYRP1 in peptidoglycan detection?
PGLYRP1 mediates intracellular peptidoglycan detection and promotes intestinal mucosal protection.
How do gamma-delta T cells respond to muramyl dipeptide?
Gamma-delta T cells show a distinct response to the NOD2 agonist muramyl dipeptide compared with other cell types.
What experimental models are used to study cellular response to muramyl dipeptide?
Common models include CRISPR knockout and knock-in cell lines, primary microglia and macrophages, intestinal epithelial cells, and in vivo immunization or tumor models.
How is cellular response to muramyl dipeptide linked to disease?
Dysregulated MDP signaling through NOD2 and RIPK2 is linked to inflammatory pathology, while controlled activation is exploited in vaccine adjuvants and cancer immunotherapy.
Conclusion
GO:0071225 cellular response to muramyl dipeptide defines the complete set of cellular changes triggered by a peptidoglycan-derived bacterial motif. The pathway is anchored by NOD2 and RIPK2, modulated by additional sensors such as PGLYRP1, and expressed differently across cell types including microglia and gamma-delta T cells. Its outputs range from inflammatory cytokine secretion to mucosal protection and adjuvant-driven adaptive immunity. Because the response is both mechanistically tractable and therapeutically relevant, it is an excellent target for CRISPR-based causal gene discovery. Knockout, point-mutation, knock-in and overexpression models, combined with transcriptomics, proteomics and functional immune assays, can resolve which genes drive MDP responses and how they might be harnessed for vaccines and cancer immunotherapy.
References
- 1. Yang C et al.. 2024. RIPK2 Is Crucial for the Microglial Inflammatory Response to Bacterial Muramyl Dipeptide but Not to Lipopolysaccharide.. Int J Mol Sci 25(21) PMID: 39519307
- 2. Cui G et al.. 2024. Muramyl Dipeptide-Presenting Polymersomes as Artificial Nanobacteria to Boost Systemic Antitumor Immunity.. ACS Appl Mater Interfaces 16(45):61655-61663 PMID: 39498882
- 3. Kerns HM et al.. 2009. The distinct response of gammadelta T cells to the Nod2 agonist muramyl dipeptide.. Cell Immunol 257(1-2):38-43 PMID: 19306993
- 4. Chen S et al.. 2025. PGLYRP1-mediated intracellular peptidoglycan detection promotes intestinal mucosal protection.. Nat Commun 16(1):1864 PMID: 39984444
- 5. Zhou CJ et al.. 2018. The Immunological Functions of Muramyl Dipeptide Compound Adjuvant on Humoral, Cellular-mediated and Mucosal Immune Responses to PEDV Inactivated Vaccine in Mice.. Protein Pept Lett 25(10):908-913 PMID: 30227812
- 6. Behr MA et al.. 2015. Freund's adjuvant, NOD2 and mycobacteria.. Curr Opin Microbiol 23:126-32 PMID: 25483349
- 7. Qu F et al.. 2019. Two novel MKKs (MKK4 and MKK7) from Ctenopharyngodon idella are involved in the intestinal immune response to bacterial muramyl dipeptide challenge.. Dev Comp Immunol 93:103-114 PMID: 30633955
- 8. Fast DJ et al.. 1997. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens.. Vaccine 15(16):1748-52 PMID: 9364678
